(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 39.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Gossamer Bio's revenue in 2025 is $44,051,000.On average, 10 Wall Street analysts forecast GOSS's revenue for 2025 to be $9,960,951,046, with the lowest GOSS revenue forecast at $7,864,188,904, and the highest GOSS revenue forecast at $11,942,447,976. On average, 10 Wall Street analysts forecast GOSS's revenue for 2026 to be $10,599,307,375, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $29,260,698,746.
In 2027, GOSS is forecast to generate $30,776,737,164 in revenue, with the lowest revenue forecast at $14,759,039,046 and the highest revenue forecast at $54,723,200,478.